Auranofin (AF) was given to 2 groups of patients, one receiving 1 mg daily (56 patients), the other 9 mg (60 patients) in a double-blind manner. Significantly fewer patients on 1 mg (7%) reduced dosage or dropped out because of side effects than did those on high dose (27%; p < 0.05). Dropouts related to skin rash while dose reduction was necessitated by self-limiting diarrhea. Significantly more patients on low dose dropped out because of lack of efficacy than did those on high dose.
|Original language||English (US)|
|Number of pages||3|
|Journal||Journal of Rheumatology|
|Issue number||Suppl. 8|
|State||Published - Jan 1 1982|
ASJC Scopus subject areas
- Immunology and Allergy